The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety,
tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with
bevacizumab in adult participants with advanced solid tumors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06265688.
Locations matching your search criteria
United States
Massachusetts
Boston
Dana-Farber Cancer InstituteStatus: Active
Name Not Available
The study is comprised of 2 parts. Part 1 involves CX-2051 dose escalation to identify
the maximum tolerated dose (MTD) of CX-2051 as monotherapy and as combination therapy
(CX-2051 combined with bevacizumab). Part 2 (dose expansion) will further assess safety
and tolerability as well as preliminarily assess antitumor activity of CX-2051 as
monotherapy and/or combination therapy in indication-specific expansion cohorts.
Lead OrganizationCytomX Therapeutics
Principal InvestigatorMonika Vainorius
